anastrozole / Generic mfg. - LARVOL DELTA

Ribociclib-Induced Liver Injury: A Rare Complication of HR-Positive, HER2-Negative Metastatic Breast Cancer Treatment (ACG 2025) - "Her anastrozole was held due to concern for possible contribution...She was treated with a high-dose prednisone taper for two months with normalization of her liver function. Our case report demonstrates grade 1 DILI with grade 4 AST and ALT elevation due to ribociclib, an uncommon culprit of DILI...Management of CDK4/6 DILI is poorly described, with only 40% of cases treated with steroids. Our case report demonstrates normalization of liver function with a course of steroids, supporting the use of steroids in patients with CDK4/6 inhibitor DILI."

Metastases • Addiction (Opioid and Alcohol) • Breast Cancer • Fatigue • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Liver Failure • Oncology • Solid Tumor • HER-2

The Breast Is Not History: Exploring a Rare Case of Metastatic Breast Cancer (MBC) to the Rectum (ACG 2025) - "Anastrozole was switched to fulvestrant (ER antagonist) and ribociclib (cyclin dependent kinase 4/6 inhibitor, held 3 months later due to rash and drug related pneumonitis). Biopsy results showing breast cancer metastases was unexpected given prior treatment and maintenance on anastrozole. The histologic findings guided transition to targeted systemic therapy, which highlights a new role of endoscopy in guiding MBC treatment.Figure: Figure 1: Flexible sigmoidoscopy images of nodular mucosa in rectum"

Clinical • Metastases • Breast Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Oncology • Pneumonia • Solid Tumor • ER • PGR

Granulomatous Inflammation Mimicking Sarcoidosis Associated with Breast Cancer Treatment (WASOG-AASOG 2025) - "Two years later, imaging revealed lymphadenopathy and a lung nodule; lymph node biopsies confirmed non-caseating granulomas.Case 2 describes a 52-year-old woman with invasive ductal carcinoma who received anastrozole and the CDK4/6 inhibitor ribociclib...Aromatase inhibitors (letrozole, anastrozole, exemestane), used in hormone receptor-positive breast cancer, suppress estrogen and promote a TH1-dominant immune profile... Collectively, we believe this is the first report of granulomatous inflammation mimicking sarcoidosis from the anti-cancer treatments received by our patients (aromatase and CDK4/6 inhibitors), which may alter local immune responses to favor a TH1 profile. These reactions can mimic cancer recurrence, making biopsy essential for accurate diagnosis. Recognizing this phenomenon is critical, and further research is needed to better understand and manage sarcoidosis-like reactions."

IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Infectious Disease • Oncology • Ovarian Cancer • Sarcoidosis • Solid Tumor • Vasculitis • CHEK2 • IFNG • IL2

TACTIVE-N: phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC) (ESMO 2025) - No abstract available

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Brain Blood Flow Responses to Stress: Sex Differences (clinicaltrials.gov) - P4 | N=22 | Completed | Sponsor: University of Wisconsin, Madison | Recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ May 2025

Trial completion • Trial completion date • CNS Disorders • Vascular Neurology

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (clinicaltrials.gov) - P3 | N=220 | Recruiting | Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: May 2030 ➔ Nov 2035 | Trial primary completion date: Jul 2028 ➔ Nov 2032

Circulating tumor DNA • Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Bireociclib plus Letrozole/Anastrozole versus Placebo plus Letrozole/Anastrozole for the Treatment of HR+/HER2- Advanced Breast Cancer: Interim Analysis of BRIGHT-3 study (ESMO 2025) - No abstract available

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Deceptive Lesions: Breast Carcinoma Presenting as a Splenic Metastasis With Gastric Wall Invasion (ACG 2025) - "This case highlights the importance of considering breast cancer in atypical presentations involving the spleen or gastrointestinal tract and highlights the critical role of immunohistochemistry in establishing the diagnosis.Case Description/ A 66-year-old woman with a history of ER+/PR–/HER2+ invasive ductal carcinoma (IDC) of the breast, diagnosed in 2017, was treated with neoadjuvant TCHP, partial mastectomy, adjuvant trastuzumab, pertuzumab, radiation, and anastrozole. She had recurrence of her breast cancer in 2021 and was switched from anastrozole to exemestane...Physicians should remain vigilant for atypical metastatic patterns in breast cancer survivors. Early recognition and multidisciplinary management are crucial, even when prognosis is poor.Figure: Figure 1: EGD showing a friable mass in the gastric fundusFigure: Figure 2: MRI showing a large splenic mass with invasion into the gastric wall"

Breast Cancer • CNS Disorders • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Renal Disease • Septic Shock • Solid Tumor • CDX2 • GATA3 • HER-2 • PGR

Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review. (PubMed, Anticancer Res) - "This report illustrates the complexity of managing breast cancer patients with OMS and reinforces the critical need for a multidisciplinary approach."

Journal • Review • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Movement Disorders • Oncology • Solid Tumor • ER • HER-2 • PGR

EUROPA: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer (clinicaltrials.gov) - P3 | N=926 | Active, not recruiting | Sponsor: Azienda Ospedaliero-Universitaria Careggi | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2025 ➔ Mar 2030

Enrollment closed • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • HER-2

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism (clinicaltrials.gov) - P4 | N=121 | Completed | Sponsor: Baylor College of Medicine | Recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ May 2025

Trial completion • Trial completion date • Endocrine Disorders • Genetic Disorders • Obesity

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=20 | Active, not recruiting | Sponsor: University of California, Irvine | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PGR

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CDK4

Comparative Effectiveness of Anastrozole, Letrozole, and Exemestane as adjuvant endocrine therapy in Postmenopausal Early-Stage Hormone-Receptor Positive Breast Cancer: A Nationwide Cohort Study [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • HEOR • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning. (PubMed, Medicina (Kaunas)) - " Through an extensive review of the literature, our findings indicate that for premenopausal women with HR-positive, HER2-negative BC with a low risk of recurrence, standard 5-year monotherapy with tamoxifen represents the optimal therapeutic management, given its favorable clinical outcomes and lower associated toxicity...In postmenopausal patients with HR-positive, HER2-negative breast cancer with a low recurrence risk, the first line of treatment is usually a standard 5-year period of treatment with aromatase inhibitors (AIs)(letrozole, anastrozole, or exemestane). On the other hand, in postmenopausal women with an intermediate to high risk, combination therapy might be needed, as well as an extension of the standard therapeutic time. Treatment consensus depends on pre- vs. postmenopausal status and recurrence risk."

Journal • Review • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jul 2031 ➔ Jul 2032 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole (clinicaltrials.gov) - P=N/A | N=16989 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • Breast Cancer • CNS Disorders • Oncology • Solid Tumor

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

In Vitro Metabolism of Doping Agents (Stanozolol, LGD-4033, Anastrozole, GW1516, Trimetazidine) by Human Seminal Vesicle and Liver Fractions. (PubMed, Metabolites) - "Gene expression and enzymatic activity in CYP3A4 and CYP1A2-major hepatic enzymes-were absent in SV-S9. Overall, these pilot study results suggest that the seminal vesicle has only a low capacity for xenobiotic metabolism, which translates into a limited role in the biotransformation of drugs and, hence, the metabolic pattern."

Journal • Preclinical • CYP1A2 • CYP2C9 • CYP2E1 • CYP3A4

Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention. (PubMed, JAMA Oncol) - "Undergoing RRM or receiving risk-stratified BC screening with medical prevention (tamoxifen or anastrozole). These results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers. Future studies evaluating the acceptability, uptake, and long-term outcomes of RRM among these women are warranted."

Journal • Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • PALB2

Multidisciplinary approach for a patient with morbid obesity and psychological issues led from the pharmacy office (PubMed, Farm Comunitarios) - "Take metformin, rosuvastatin, and anastrozole...In the emergency department, he undergoes an ultrasound and intravenous analgesics that relieve the pain, diagnoses nephritic colic and prescribes metamizole and tramadol/paracetamol...The pharmacist makes a second referral to the doctor, with a written communication of suspicion of Herpes Zoster, the doctor accepts the intervention and changes the treatment by putting Valacyclovir, paracetamol/codeine and capsaicin cream. The patient returns to the pharmacy reporting that the doctor was surprised that it was a pharmacist who gave the correct diagnosis."

Journal • Breast Cancer • Diabetes • Dyslipidemia • Genetic Disorders • Herpes Zoster • Metabolic Disorders • Obesity • Oncology • Pain • Solid Tumor • Varicella Zoster

Breast carcinoma in a patient with neurofibromatosis type 1 and huge plexiform neurofibroma of the contralateral breast: a case report. (PubMed, BMC Womens Health) - "It is known that women with NF1 have a higher risk of developing breast cancer, as demonstrated in our case. These patients could benefit from an early start of breast cancer screening, which could lead to an early diagnosis of early-stage tumors and a better prognosis. Additionally, enhanced access to healthcare centers and intensive surveillance could contribute significantly to better outcomes."

Journal • Breast Cancer • Genetic Disorders • Musculoskeletal Pain • Neurofibromatosis • Oncology • Pain • Solid Tumor • NF1

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) - P1/2 | N=44 | Active, not recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

TRIO-US B-12 TALENT: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - P2 | N=88 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

A Rare Case of Metastasis of Renal Cell Carcinoma to Thyroid Gland presenting as Neck Mass, Four Years After Nephrectomy. (ENDO 2025) - "Her cancer history also included right breast ductal carcinoma in situ (DCIS), diagnosed in 2011, and left breast invasive ductal carcinoma (IDC) in 2019, for which she underwent lumpectomy and currently on anastrozole.The patient had been disease-free post-surgery with routine follow-up, including CT scans and renal ultrasounds, whit no signs of recurrence...These findings further supported the diagnosis of thyroid metastasis from RCC.This case underscores the importance of ongoing surveillance in RCC survivors, even many years after initial treatment, as metastasis can occur long after the primary disease is considered "disease-free." Thyroid metastasis from RCC, while rare, should be considered in the differential diagnosis of thyroid nodules in patients with a history of RCC, mainly when unusual presentation patterns occur. This case contributes to understanding RCC metastasis to the thyroid, emphasizing the need for vigilance in follow-up care and..."

Clinical • Breast Cancer • Endocrine Disorders • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • BRAF • CA9 • MME • NKX2-1 • PAX8